STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACBM
  4. [10-Q] ACRO BIOMEDICAL CO., LTD. Quarterly Earnings Report

Acro Biomedical (ACBM) flags going concern risk amid cash shortage and no revenue

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
10-Q

Rhea-AI Filing Summary

Acro Biomedical Co., Ltd. reported no revenue for the three and six months ended June 30, 2026, continuing a multi‑year trend of no sales since December 31, 2022. For the six‑month period, operating expenses were $77,825, primarily general and administrative and public company costs, leading to a net loss of $65,130 versus $25,863 a year earlier.

Cash was only $3,648 and current liabilities were $448,437, resulting in a stockholders’ deficit of $444,789. The company’s auditor and management state that these conditions, along with the absence of revenue and product output, raise substantial doubt about its ability to continue as a going concern. Operations are being funded almost entirely by a minority stockholder, to whom $384,287 is owed.

The company has no full‑time employees; its sole officer serves part‑time without pay. Management reports material weaknesses in internal control, including lack of segregation of duties and reliance on consultants. The common stock trades on the OTC Pink Limited Market on an unsolicited‑only basis, with no market makers and limited liquidity.

Positive

  • None.

Negative

  • Substantial doubt about going concern: minimal cash, no revenue since 2022, recurring losses, and auditor & management going‑concern language.
  • Working capital deficit of $444,789 as of June 30, 2026, reflecting $3,648 in current assets against $448,437 in current liabilities.
  • Net loss increased to $65,130 for the six months ended June 30, 2026, from $25,863 in the prior‑year period, driven by higher operating expenses.
  • Severe control weaknesses: ineffective disclosure controls, material weaknesses in internal control, and no segregation of duties with one part‑time officer handling all key roles.
  • Extremely limited trading liquidity: stock quoted on the OTC Pink Limited Market as an unsolicited‑only security with no market makers and potential difficulty for investors to sell.

Filing Explained

Six-month operating cash use was $60,325 versus $59,875 of minority-stockholder advances, with no committed financing disclosed.

This unaudited quarterly report updates Acro Biomedical’s liquidity through June 30, 2026: during the six months, the company received $59,875 of advances from a minority stockholder while using $60,325 in operating activities.

Because the advances are due on demand and the company discloses no agreements or understandings for financing, this support is not a committed future funding facility.

As of the report date, the company had no orders for products, so future operating funding remains tied in the filing to obtaining additional funds and generating product revenue.

Future filings would need to establish whether additional funding is obtained and product revenue begins; this report discloses neither a financing agreement nor product orders.

Cash balance $3,648 Cash as of June 30, 2026
Net loss $65,130 Six months ended June 30, 2026
Operating expenses $77,825 Six months ended June 30, 2026, general and administrative and professional fees
Stockholders’ deficit $444,789 Total stockholders’ deficit as of June 30, 2026
Due to related parties $385,387 Amounts owed to related parties as of June 30, 2026
Liability forgiveness income $20,000 Other income from liability forgiveness in the six months ended June 30, 2026
Working capital deficit change $57,825 Increase in working capital deficit from December 31, 2025 to June 30, 2026
Advances from minority stockholder $59,875 Financing cash flows from a minority stockholder in the six months ended June 30, 2026
going concern financial
"These factors raise substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
imputed interest financial
"The Company has imputed interest at the rate of 4% on the advances made"
liability forgiveness financial
"the Company recorded liability forgiveness of $20,000 as other income"
Pink Limited Market market
"our stock being traded on the OTC Market Group’s Pink Limited Market"
A pink limited market is a segment of the stock market where shares of smaller or newer companies are traded, often with fewer regulations and less oversight than larger markets. It matters to investors because these markets can offer opportunities for growth but also carry higher risks due to less transparency and stability, similar to a marketplace where products are less tested and might be more uncertain.
segregation of duties financial
"material weaknesses due to the absence of segregation of duties"
Segregation of duties is the practice of splitting important financial and operational tasks among different people so no single person can both start, approve, and record the same transaction — like having one person ring up sales and another person deposit the money. For investors, it matters because this simple separation reduces the chance of mistakes or fraud, helps ensure financial reports are trustworthy, and lowers legal and reputation risk that can affect a company’s value.

FAQ

How did Acro Biomedical (ACBM) perform financially in the six months ended June 30, 2026?
Acro Biomedical reported a net loss of $65,130 for the six months ended June 30, 2026, with no revenue. Operating expenses were $77,825, primarily general and administrative and public company costs, compared with a $25,863 net loss in the prior‑year period.

What is Acro Biomedical (ACBM)’s cash position and working capital as of June 30, 2026?
As of June 30, 2026, Acro Biomedical held $3,648 in cash and had current liabilities of $448,437, resulting in a working capital deficit of $444,789. The balance sheet shows total assets of $3,648 and a total stockholders’ deficit of $444,789.

Does Acro Biomedical (ACBM) face going concern risks?
Yes. Management and the independent auditor state that there is substantial doubt about Acro Biomedical’s ability to continue as a going concern due to minimal cash, no revenue since 2022, recurring operating losses, negative cash flows, and a significant stockholders’ deficit.

What internal control issues does Acro Biomedical (ACBM) report?
Acro Biomedical reports material weaknesses in internal control over financial reporting, including lack of segregation of duties, no qualified accounting staff, and heavy reliance on third‑party consultants. Its sole director serves as both CEO and CFO on a part‑time basis, and disclosure controls are deemed ineffective.

What is the trading status of Acro Biomedical (ACBM) common stock?
Acro Biomedical’s common stock is quoted on the OTC Market Group’s Pink Limited Market as an unsolicited‑only security. There are no market makers, no published proprietary broker‑dealer quotes, and investors may experience wider spreads, volatility, and difficulty selling shares.

Did Acro Biomedical (ACBM) record any notable non-operating items in the period?
Yes. During the six months ended June 30, 2026, Acro Biomedical recorded $20,000 of liability forgiveness as other income when a payment previously received was forfeited as compensation for non‑performance and the related order was terminated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
10-Q Quarterly Reports: What Changes Quarter to Quarter →

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the quarterly period ended June 30, 2026

 

 

☐

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________

 

Commission File Number: 000-55643

 

ACRO BIOMEDICAL CO., LTD.

(Exact name of registrant as specified in its charter)

 

Nevada

 

47-1950356

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

12175 Visionary Way , Suite 1160; Fishers, Indiana 46038

(Address of principal executive offices)

 

(317) 286-6788

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes     ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes     ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a small reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated Filer

☒

Smaller reporting company

☒

 

 

Emerging growth company

☐

 

If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ☒ Yes      ☐ No

 

Securities registered pursuant to Section 12(b) of the Exchange Act: None

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 60,042,000 shares of common stock on August 5, 2026.

 

 

 

 

TABLE OF CONTENTS

 

 

 

 

Page No.

 

PART I - FINANCIAL INFORMATION

 

 

Item 1.

Financial Statements.

 

4

 

 

Unaudited Condensed Balance Sheets as of June 30, 2026, and December 31, 2025

 

4

 

 

Unaudited Condensed Statements of Operations for the six months ended June 30, 2026, and 2025

 

5

 

 

Unaudited Condensed Statements of Changes in Stockholders’ Deficit for the six months ended June 30, 2026, and 2025

6

 

 

Unaudited Condensed Statements of Cash Flows for the six months ended June 30, 2026, and 2025

 

7

 

 

Notes to Unaudited Condensed Financial Statements.

 

8

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

11

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

 

14

 

Item 4.

Controls and Procedures.

 

15

 

 

 

 

 

 

PART II – OTHER INFORMATION

 

 

 

Item 6.

Exhibits.

 

16

 

 

 
2

Table of Contents

 

FORWARD LOOKING STATEMENTS

 

This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future matters are forward-looking statements.

 

Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our report on Form 10-K for the year ended December 31, 2025, in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q and in other reports that we file with the SEC. You are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.

 

We file reports with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us. You can also read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain additional information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.

 

We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

 

 
3

Table of Contents

 

Item 1. Financial Statements

 

ACRO BIOMEDICAL CO., LTD.

Condensed Balance Sheets

 

 

 

June 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

 

 

(Unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash

 

$3,648

 

 

$4,098

 

Prepaid expenses

 

 

-

 

 

 

10,000

 

Total Current Assets

 

 

3,648

 

 

 

14,098

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$3,648

 

 

$14,098

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$63,050

 

 

$55,550

 

Deferred revenue

 

 

-

 

 

 

20,000

 

Due to related parties

 

 

385,387

 

 

 

325,512

 

Total Current and Total Liabilities

 

 

448,437

 

 

 

401,062

 

 

 

 

 

 

 

 

 

 

Stockholders' Deficit

 

 

 

 

 

 

 

 

Preferred stock: 25,000,000 authorized; $0.001 par value; no shares issued and outstanding

 

 

-

 

 

 

-

 

Common stock: 100,000,000 authorized; $0.001 par value; 60,042,000 shares issued and outstanding

 

 

60,042

 

 

 

60,042

 

Additional paid-in capital

 

 

32,319,240

 

 

 

32,311,935

 

Accumulated deficit

 

 

(32,824,071)

 

 

(32,758,941)

Total Stockholders’ Deficit

 

 

(444,789)

 

 

(386,964)

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

 

$3,648

 

 

$14,098

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 
4

Table of Contents

 

ACRO BIOMEDICAL CO., LTD.

Condensed Statements of Operations

(Unaudited)

 

 

 

Three Months Ended

 

 

Six months ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

17,554

 

 

 

13,614

 

 

 

77,825

 

 

 

22,548

 

Total operating expenses

 

 

17,554

 

 

 

13,614

 

 

 

77,825

 

 

 

22,548

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(17,554)

 

 

(13,614)

 

 

(77,825)

 

 

(22,548)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liability forgiveness

 

 

-

 

 

 

-

 

 

 

20,000

 

 

 

-

 

Interest expense - related parties

 

 

(3,802)

 

 

(1,948)

 

 

(7,305)

 

 

(3,315)

Total other income (expense)

 

 

(3,802)

 

 

(1,948)

 

 

12,695

 

 

 

(3,315)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(21,356)

 

$(15,562)

 

$(65,130)

 

$(25,863)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per share of common stock

 

$(0.00)

 

$(0.00)

 

$(0.00)

 

$(0.00)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares of common stock outstanding

 

 

60,042,000

 

 

 

60,042,000

 

 

 

60,042,000

 

 

 

60,042,000

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 
5

Table of Contents

 

ACRO BIOMEDICAL CO., LTD.

Condensed Statements of Changes in Stockholders’ Deficit

(Unaudited)

 

For the Three and Six months ended June 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Total

 

 

 

Preferred Stock

 

 

Common Stock

 

 

Paid in

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Deficit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2025

 

 

-

 

 

$-

 

 

 

60,042,000

 

 

$60,042

 

 

$32,311,935

 

 

$(32,758,941)

 

$(386,964)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Imputed interest on related party loans

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

3,503

 

 

 

-

 

 

 

3,503

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(43,774)

 

 

(43,774)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2026

 

 

-

 

 

 

-

 

 

 

60,042,000

 

 

 

60,042

 

 

 

32,315,438

 

 

 

(32,802,715)

 

 

(427,235)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Imputed interest on related party loans

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

3,802

 

 

 

-

 

 

 

3,802

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(21,356)

 

 

(21,356)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2026

 

 

-

 

 

$-

 

 

 

60,042,000

 

 

$60,042

 

 

$32,319,240

 

 

$(32,824,071)

 

$(444,789)

 

For the Three and Six months ended June 30, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Total

 

 

 

Preferred Stock

 

 

Common Stock

 

 

Paid in

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Deficit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2024

 

 

-

 

 

$-

 

 

 

60,042,000

 

 

$60,042

 

 

$32,302,781

 

 

$(32,657,795)

 

$(294,972)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Imputed interest on related party loans

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,367

 

 

 

-

 

 

 

1,367

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(10,301)

 

 

(10,301)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2025

 

 

-

 

 

 

-

 

 

 

60,042,000

 

 

 

60,042

 

 

 

32,304,148

 

 

 

(32,668,096)

 

 

(303,906)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Imputed interest on related party loans

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,948

 

 

 

-

 

 

 

1,948

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

(15,562)

 

 

(15,562)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2025

 

 

-

 

 

$-

 

 

 

60,042,000

 

 

$60,042

 

 

$32,306,096

 

 

$(32,683,658)

 

$(317,520)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 
6

Table of Contents

 

ACRO BIOMEDICAL CO., LTD.

Condensed Statements of Cash Flows

(Unaudited)

 

 

 

 Six months ended

 

 

 

 June 30,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$(65,130)

 

$(25,863)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Imputed interest - related parties

 

 

7,305

 

 

 

3,315

 

Liability forgiveness

 

 

(20,000)

 

 

-

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses

 

 

10,000

 

 

 

(35,000)

Accounts payable

 

 

7,500

 

 

 

(58,967)

Net cash used in operating activities

 

 

(60,325)

 

 

(116,515)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Advances from related parties

 

 

59,875

 

 

 

116,065

 

Net cash provided by financing activities

 

 

59,875

 

 

 

116,065

 

 

 

 

 

 

 

 

 

 

Net change in cash

 

 

(450)

 

 

(450)

Cash at beginning of period

 

 

4,098

 

 

 

476

 

Cash at end of period

 

$3,648

 

 

$26

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Cash paid for income taxes

 

$-

 

 

$-

 

Cash paid for interest

 

$-

 

 

$-

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 
7

Table of Contents

 

ACRO BIOMEDICAL CO., LTD.

Notes to the Unaudited Condensed Financial Statements

June 30, 2026

 

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Acro Biomedical Co., Ltd. (the “Company”) is a Nevada corporation incorporated on September 24, 2014, under the name Killer Waves Hawaii, Inc. On January 30, 2017, the Company’s corporate name was changed to Acro Biomedical Co., Ltd.

 

The Company’s business is the sale of cordyceps related products. Cordyceps is a fungus that is used in traditional Chinese medicine. During the second and third quarters of 2021, the Company engaged consultants to take the initial steps to develop and implement a research and development and marketing program. The research and development efforts did not generate any product. The contracts with the consultants expired in May 2023 and August 2023. No revenue, new product or new marketing opportunity was generated from these efforts and the Company has had limited operations since that date.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Unaudited Interim Financial Statements

 

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2025, have been omitted; and these unaudited interim financial statements should be read in conjunction with the audited financial statements and the footnotes thereto for the year ended December 31, 2025, included within the Company’s annual report on Form 10-K for the year ended December 31, 2025.

 

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.

 

Segment Information

 

Our Chief Executive Officer (“CEO”) is the chief operating decision maker who reviews financial information for purposes of allocating resources and evaluating financial performance. Accordingly, we determined we operate in a single reporting segment.

 

Our CEO assesses performance and decides how to allocate resources primarily based on net income, which is reported on our Statements of Operations. Total assets on the Balance Sheets represent our segment assets.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

 

Net Loss Per Share of Common Stock

 

The Company has adopted ASC Topic 260,” Earnings per Share” which requires presentation of basic earnings per share on the face of the statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share computation. In the accompanying financial statements, basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common stock issuable through contingent share arrangements, stock options and warrants unless the result would be antidilutive. There were no potentially dilutive shares of common stock outstanding for the six months ended June 30, 2026, and 2025.

 

 
8

Table of Contents

 

 

Recent Accounting Pronouncements

 

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.

 

New Accounting Pronouncements Issued and Not Yet Adopted

 

In December 2025, the FASB issued ASU No. 2025-12, Codification Improvements. The ASU addresses thirty-three items, representing the changes to the Codification that (1) clarify, (2) correct errors, or (3) make minor improvements. Generally, the amendments in this Update are not intended to result in significant changes for most entities. The ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2026. The adoption method of this ASU may vary, on an issue-by-issue basis. Early adoption is permitted. We are currently evaluating the provisions of this ASU and do not expect this ASU to have a material impact on our financial statements.

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. The ASU provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-11.

 

The Company has reviewed all other recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on the Company’s financial statements.

 

NOTE 3 – GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company had minimal cash at June 30, 2026, had no revenue for the six months ended June 30, 2026, or the years ended December 31, 2025, and 2024, incurred a loss from operations for the six months ended June 30, 2026 as well as prior years, had negative cash flow from operations for the six months ended June 30, 2026, and had a stockholders’ deficit as of June 30, 2026. To date, the Company has not generated any revenue subsequent to December 31, 2022, and did not generate any products from its research and development activities. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date of the financial statements being issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025, financial statements, has expressed substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Management recognizes that the Company must obtain additional funds and implement its business plans. However, because of no revenue and the absence of any active trading market for its common stock, its financial condition and its lack of an operating history, the Company may not be able to raise funds for capital expenditures, working capital and other cash requirements. The Company’s primary source of funds for the six months ended June 30, 2026, has been advances from a minority stockholder. This stockholder has continued to be the Company’s principal source of funds and the Company will have to continue to rely on advances from the minority stockholder. If the Company cannot generate revenue from its products, it may not be able to continue in its business.

 

NOTE 4 - RELATED PARTY TRANSACTIONS

 

At June 30, 2026, and December 31, 2025, the Company owed $1,100 to a former chief executive officer for non-interest-bearing advances made to or operating expenses paid on behalf of the Company. These advances are due on demand with no formal terms of repayment.

 

During the three months ended June 30, 2026, and 2025, such minority stockholder paid operating expenses of $10,279 and $93,759 on behalf of the Company, respectively.

 

 
9

Table of Contents

 

During the six months ended June 30, 2026, and 2025, a minority stockholder paid operating expenses of $59,875 and $116,065, on behalf of the Company, respectively.

 

At June 30, 2026, and December 31, 2025, the Company owed $384,287 and $324,412 to the minority stockholder referred to in the preceding paragraph for non-interest-bearing advances made to or operating expenses paid on behalf of the Company, respectively. These advances are due on demand.

 

The Company has imputed interest at the rate of 4% on the advances made to or operating expenses paid on behalf of the Company. Imputed interest amounted to $7,305 and $3,315, during the six months ended June 30, 2026, and 2025, respectively.

 

At June 30, 2026 and December 31, 2025, the Company had aggregate amounts due to related parties of $385,387 and $325,512, respectively.

 

NOTE 5 – LIABILITY FORGIVENESS

 

During the six months ended June 30, 2026, $20,000 paid to the Company was forfeited as compensation for non-performance and the order was terminated. As a result, the Company recorded liability forgiveness of $20,000 as other income in the Statement of Operations.

 

NOTE 6 - SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events that have occurred after the date of the balance sheet through the date of issuance of these financial statements and determined that no subsequent event requires recognition or disclosure to the financial statements.

 

 
10

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. See “Forward- Looking Statements.”

 

Overview

 

Since January 30, 2017, following a change of control, we have been engaged in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. Our business has involved the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. We have not had any sales subsequent to December 31, 2022, through the date of this report and as of the date of this report we do not have any orders for products.

 

All of our sales to date have been sales of cordyceps related products except that, in the quarter ended September 30, 2018, we sold metallothionein MT-3 elizer, a product that we do not currently sell. Cordyceps is a fungus that is used in traditional Chinese medicine. Cordyceps sinensis has been described as a medicine in old Chinese medical books and Tibetan medicine. It is a rare combination of a caterpillar and a fungus and found at altitudes above 4500m in Sikkim. We may also seek to market other products which we see as complementary to our present products; however, we have not entered into negotiations with respect to the distribution of other products, and we cannot assure you that we will be able to market any other products.

 

We believe that, since a major market for cordyceps products is China, our customers have significant customers in China and our business was impacted by COVID-19 and steps taken by the government of China, particularly its Zero COVID policy, which was relaxed in December 2022. Further, we also cannot assure you the political instability in Hong Kong will not affect our sales, since our customers in 2017 and 2018 were Hong Kong based customers who sold their products in the PRC and none of these customers has made purchases from us since the quarter ended December 31, 2018. We cannot assure you that these factors will not affect our ability to generate revenue in the future and, to the extent that any of these factors affect our ability to generate revenue, we may not be able to continue in business.

 

At present, we have no full-time employees. Our only employee is our chief executive officer who works for us on a part-time basis and does not receive compensation. We face significant risks in developing our business, including, but not limited to, our ability to raise the necessary financing either through the sale of debt or equity securities or through a loan facility, our ability to increase our customer base and supply chain, our ability to increase our gross margins, our ability to hire and retain qualified research and development, marketing and administrative personnel, our ability to develop products and to market in the United States and other western markets any products we may develop, our ability to comply with any government regulations relating to the manufacture, distribution and marketing any products we develop. We cannot assure you that we can or will develop any products or generate revenue or profits in the future.

 

During the period from May 2021 through August 2023, we engaged consultants who performed research and development services as well as selling, general and administrative services, all in connection with a proposed product – a cordyceps-infused chicken feed. These research and development activities did not generate a marketable product, and we cannot assure you that we will seek to continue the development of this product or any other product. We do not have the funds or the revenue stream for us to hire any consultants or employees. Our selling, general and administrative expenses do not include any compensation for our chief executive officer, who serves without compensation and is responsible for our purchases, sales and directed our research and development program. As a result, the results of our operations do not reflect costs that would normally be associated with a chief executive officer who performs such functions.

 

 
11

Table of Contents

 

We require funds for our operations. At June 30, 2026, we had nominal cash and no accounts receivable. Although we may seek to raise funds in the equity market, we have no agreements or understandings with respect to any funding, and we can give no assurance as to the availability or terms of any such financing. Because of our financial condition, the lack of sales subsequent to December 31, 2022, along with the absence of an active market for our stock and our stock being traded on the OTC Market Group’s Pink Limited Market. Our common stock was previously listed on the OTC Market Group’s Expert Market, as a result of which our common stock was not eligible for proprietary broker-dealer quotes. As a result, there are no market makers for our common stock. At present, our stock is not eligible for proprietary broker-dealer quotations and all quotes reflect unsolicited customer orders. Unsolicited only stocks have a higher risk of wider spreads, increased volatility, and price dislocations. Investors may have difficulty selling this stock. An initial review by a broker- dealer under SEC Rule 15c2-11 is required for brokers to publish competing quotes and provide continuous market making. Accordingly, there are no published quotes for our common stock and we cannot assure you that a broker-dealer will take the necessary steps to make a market in our common stock. This lack of a trading market for our common stock together with risk related to political and legal situation in Hong Kong, may be difficult for us to raise funds in the equity market, and, if we are able to raise funds our stockholders may suffer significant dilution. Our primary source of funds for the years ended December 31, 2025, and 2024 and the six months ended June 30, 2026 has been advances from a minority stockholder. This stockholder has continued to be our principal source of funds. We cannot assure you that he will continue to provide funding for us.

 

To the extent that we implement our business plan, we anticipate that we will incur marketing and other expenses without any assurance that such expenses will generate any significant revenue, cash flow from operations or net income. Because of our cash position, we may seek to use equity-based compensation for our employees and independent contractors. Because of our low cash position, we may rely on loans from stockholders or related parties, although we do not have any agreements or understandings at this time, and we may issue equity to attract employees and consultants to help us develop our business plan. Because we are quoted on the Pink Limited Market, our common stock is an unsolicited only stock and there are no market makers for our common stock, potential employees or consultants may be reluctant to accept common stock as compensation. We cannot assure you that we will be able to develop or market products, in which case we may continue to be unable to generate revenue.

 

Results of Operations

 

The following summary of our results of operations should be read in conjunction with our unaudited condensed financial statements for the period ended June 30, 2026, which are included herein.

 

Our operating results for the six months ended June 30, 2026, and 2025 and the changes between those periods for the respective items are summarized as follows.

 

Results of Operations for the three months ended June 30, 2026, and 2025

 

For the three months ended June 30, 2026 and 2025, we had no revenue or cost of revenue.

 

For the three months ended June 30, 2026 and 2025, our operating expenses were $17,554 and $13,614, which are primarily related to general and administrative expenses and professional fees relating to our status as a public company, respectively.

 

For the three months ended June 30, 2026 and 2025, we incurred interest expense to two minority stockholders of $3,802 and $1,948, respectively.

 

We had a net loss of $21,356 for the three months ended June 30, 2026, and $15,562 for the three months ended June 30, 2025. The increase in net loss of $5,794 was due to an increase in operating expenses of $3,940 and interest expenses -related parties of $1,854.

 

 
12

Table of Contents

 

Results of Operations for the six months ended June 30, 2026, and 2025

 

For the six months ended June 30, 2026, and 2025, we had no revenue or cost of revenue.

 

For the six months ended June 30, 2026, and 2025, our operating expenses were $77,825 and $22,548, which are primarily related to general and administrative expenses and professional fees relating to our status as a public company, respectively.

 

For the six months ended June 30,2026 and 2025, we incurred interest expense to two minority stockholders of $7,305 and $3,315, respectively

 

During the six months ended June 30, 2026, $20,000 paid to the Company was forfeited as compensation for non-performance and the order was terminated. As a result, the Company recorded gain from liability forgiveness of $20,000.

 

We had a net loss of $65,130 for the six months ended June 30, 2026, and $25,863 for the six months ended June 30, 2025. The increase in net loss of $39,267 was due to an increase in operating expenses of $55,277 and interest expenses -related party of $3,990, offset by an increase in gain from liabilities forgiveness of $20,000.

 

Liquidity and Capital Resources

 

Balance Sheet Data:

 

The following table summarizes our changes in working capital from December 31, 2025, to June 30, 2026:

 

 

 

June 30,

 

 

December 31,

 

 

 

 

 

 

2026

 

 

2025

 

 

Change

 

Current Assets

 

$3,648

 

 

$14,098

 

 

$(10,450)

Current Liabilities

 

$448,437

 

 

$401,062

 

 

$47,375

 

Working Capital

 

$(444,789)

 

$(386,964)

 

$(57,825)

 

As of June 30, 2026, our current assets were $3,648 and our current liabilities were $448,437 which resulted in working capital deficiency of $444,789. As of June 30, 2026, current assets were comprised of $3,648 in cash, compared to $4,098 in cash, $10,000 in prepaid expenses as of December 31, 2025.

 

As of June 30, 2026, current liabilities were comprised of $63,050 in accounts payable, $385,387 in due to related party, compared to $55,550 in accounts payable, $325,512 in due to related party and $20,000 in deferred revenue as of December 31, 2025.

 

As of June 30, 2026, our working capital (deficiency) increased by $57,825 from a $386,964 working capital deficiency at December 31, 2025, to $444,789 of working capital deficiency at June 30, 2026, primarily due to a decrease in current assets of $10,450 and an increase in current liabilities of $47,375.

 

Cash Flow Data:

 

The following table summarizes our cash flows for the six months ended June 30, 2026, and 2025:

 

 

 

Six months ended

 

 

 

 

 

 

June 30,

 

 

 

 

 

 

2026

 

 

2025

 

 

Change

 

Cash used in operating activities

 

$(60,325)

 

$(116,515)

 

$56,190

 

Cash provided by financing activities

 

 

59,875

 

 

 

116,065

 

 

 

(56,190)

Cash end of period

 

$3,648

 

 

$26

 

 

$3,622

 

 

 
13

Table of Contents

 

Cash Flows from Operating Activities

 

We have not generated positive cash flows from operating activities. For the six months ended June 30, 2026, net cash flows used in operating activities were $60,325, consisting of a net loss of $65,130, increased by liabilities forgiveness of $20,000 and reduced by imputed interest -related parties of $7,305, accounts payable of $7,500 and prepaid expenses of $10,000.

 

For the six months ended June 30, 2025, net cash flows used in operating activities were $116,515, consisting of a net loss of $25,863, increased by prepaid expenses of $35,000, accounts payable of $58,967 and reduced by imputed interest-related parties of $3,315.

 

Cash Flows from Investing Activities

 

For the six months ended June 30, 2026, and 2025, no cashflows were provided by or used in investing activities.

 

Cash Flows from Financing Activities

 

During the six months ended June 30,2026 and 2025, we received $59,875 and $116,065 advances from a minority stockholder to pay certain operating expenses on behalf of the Company, respectively.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company had minimal cash at June 30, 2026, had no revenue for the six months ended June 30, 2026, and the years ended December 31, 2025, and 2024, and incurred a loss from operations for the six months ended June 30, 2026, as well as prior years, had negative cash flow from operations for the six months ended June 30, 2026, and had a stockholders’ deficit as of June 30, 2026, and December 31, 2025. To date, the Company has not generated any revenue subsequent to December 31, 2022 and did not generate any products from its research and development activities. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date of the financial statements being issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025, financial statements, has expressed substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Management recognizes that the Company must obtain additional funds and implement its business plans. However, because of no revenue and the absence of any active trading market for its common stock, its financial condition and its lack of an operating history, the Company may not be able to raise funds for capital expenditures, working capital and other cash requirements. The Company’s primary source of funds for the six months ended June 30, 2026, has been advances from a minority stockholder. This stockholder has continued to be the Company’s principal source of funds and the Company will have to continue to rely on advances from the minority stockholder. If the Company cannot generate revenue from its products, it may not be able to continue in its business.

 

Critical Accounting Policy and Estimates

 

Our critical accounting policies are disclosed in the Note 2 of Notes to Financial Statements.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Item 3: Quantitative and Qualitative Disclosures About Market Risk

 

Smaller reporting companies are not required to provide the information required by this item.

 

 
14

Table of Contents

 

Item 4: Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We conducted an evaluation of the effectiveness of our disclosure controls and procedures (“Disclosure Controls”), as defined by Rules 13a-15(e) and 15d- 15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of June 30, 2026, the end of the period covered by this Quarterly Report on Form 10-Q. The Disclosure Controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer, which positions are held by the same person and who is our only employee and who does not work for us on a full-time basis. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and our chief financial officer, who are the same person, concluded that, due to the inadequacy of our internal controls over financial reporting, our sole employee being our chief executive and financial officer and our limited internal audit function, our disclosure controls were not effective as of June 30, 2026, such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the president and treasurer, as appropriate to allow timely decisions regarding disclosure.

 

Changes in Internal Control over Financial Reporting

 

As reported in our annual report on Form 10-K for the year ended December 31, 2025, management has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel and excessive reliance on third party consultants for accounting, financial reporting and related activities. The lack of any separation of duties, with the same person, who is our only employee who serves as both chief executive officer and chief financial officer, who is our sole director and who does not have an accounting background and serves on a part-time basis, makes it unlikely that we will be able to implement effective internal controls over financial reporting in the near future.

 

During the period ended June 30, 2026, there was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 
15

Table of Contents

 

PART II – OTHER INFORMATION

 

Item 6: Exhibits

 

The following exhibits are included as part of this report:

 

Exhibits

 

Exhibit Number

 

Description of Exhibits

(31)

 

Rule 13a-14(a)/15d-14(a) Certification

31.1*

 

Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer

31.2*

 

Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial and Accounting

(32)

 

Section 1350 Certification

32.1*

 

Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer

32.2*

 

Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial and Accounting Officer

101*

 

Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q.

104*

 

Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.

__________ 

*

Filed herewith

**

Furnished herewith

 

 
16

Table of Contents

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

ACRO BIOMEDICAL CO., LTD.

 

 

 

 

 

Dated: August 13, 2026

By:

/s/ Yu-Ting, Su

 

 

 

Yu-Ting, Su

 

 

 

Chief Executive Officer and Chief

 

 

 

Financial Officer

 

 

 
17

 

Source: View Original Filing on SEC EDGAR